Please login to the form below

Not currently logged in
Email:
Password:

Bayer wins FDA approval for MS electronic autoinjector and app

US regulator gives green light to Betaconnect and myBETA app

Bayer

The FDA has approved Bayer’s electronic autoinjector Betaconnect and associated myBETA app for multiple sclerosis patients to use.

The app - created by Medicom Innovation Partner - uses Bluetooth technology to connect with the autoinjector that administers Betaseron (interferon beta-1b), so patients can access and share their data with healthcare professionals via a mobile phone or computer.

“Since introducing the first FDA approved treatment option for relapsing remitting multiple sclerosis patients more than two decades ago, we’ve listened closely to the community to understand their needs and how we can support them,” said Mark Rametta, Bayer’s medical director for Neurology.

The app and the Betaconnect navigator also includes around-the-clock access to nurse support.

Patients using other injection methods to take Betaseron can also manually enter injection information into the app and can participate in sharing their data with their healthcare team.

The myBETA app will be available for free download at the Apple store, Google Play or Betaseron.com in mid-July.

Article by
Gemma Jones

19th June 2017

From: Marketing, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

How to plan, execute and refine an excellent congress experience
Medical congresses are one of the most important and intensive marketing activities a company can undertake. Here, Account Director Dolan Desai and Senior Creative Copywriter Dale Choate give you the...
Jo Fearnhead-Wymbs A year in the role as patient engagement director
A year of patient-cenricity… helping our clients have an even greater impact on patient outcomes...
Launch Sequencing Case Study
...

Infographics